An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Receiving Folotyn® (Pralatrexate)
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Levofolinic acid (Primary) ; Pralatrexate
- Indications Mucositis
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 30 Apr 2015 New trial record